The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Malignant cells displayed weak to moderate cytoplasmic immunoreactivity often combined with additional nuclear positivity. A few cases of malignant lymphomas, renal and urothelial cancer were strongly stained. Most cases of skin and testicular cancer as well as several malignant gliomas were negative.
A majority of malignancies displayed moderate cytoplasmic staining combined with a few cases of nuclear positivity. Strong staining was observed in a few cases of endometrial, prostate and ovarian cancers. Malignant gliomas, melanomas, skin and testicular cancers were negative or weakly stained.
Validation
Two (or more) antibodies yielding similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data
